2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 166

Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Abstract Number: 167

Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
Abstract Number: 169

Addressing the Pediatric Rheumatology Workforce Shortage: Is Early Exposure Enough?
Abstract Number: 170

Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE
Abstract Number: 171

Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis
Abstract Number: 172

Improved Self-efficacy and Knowledge in Pediatric Rheumatology Among General Pediatric Residents Following the Introduction of a Standardized Teaching Series
Abstract Number: 173

Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement
Abstract Number: 174

Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients
Abstract Number: 175

Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Abstract Number: 176

Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 177

Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)
Abstract Number: 178

HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic
Abstract Number: 179

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 180

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].